Atea Pharmaceuticals Inc (NAS:AVIR)
$ 3.71 -0.25 (-6.31%) Market Cap: 312.47 Mil Enterprise Value: -242.18 Mil PE Ratio: 0 PB Ratio: 0.60 GF Score: 43/100

Atea Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript

Jan 10, 2024 / 06:30PM GMT
Release Date Price: $3.35 (-2.90%)
Eric Joseph JPMorgan Chase;Co;Moderator

&-

Good morning. I'm Eric Joseph, Senior Biotech Analyst with JPMorgan. And our next presenting company is a Atea Pharmaceuticals and presenting on behalf of the company's Chief Executive Officer, Jean-Pierre Sommadossi. There is a Q&A after the presentation. We'll bring mikes around for those who have a question, then folks can submit questions via the portal who are tuning in via webcast. So thank you.

Jean;Pierre Sommadossi Atea Pharmaceuticals
Inc. - Founder, Chairman, CEO

Thank you. I appreciate. Good morning. And before I begin, I would like to thank JP Morgan for the opportunity to present today. We have some exciting news updates for both clinical program, COVID-19 and HCV that I am pleased to share with you today. And before I begin the usual forward-looking statements, and we encourage you for further information found in our most recent regulatory filings.

So I'd say our mission is focused on the discovery and development of antiviral drugs for the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot